Analysis and Suggestions for Business Model of eBayEachnet

EBAY易趣网和淘宝网是目前中国电子商务中经常被提及的两个对手。2002年时，EBAY易趣曾经一枝独秀，但在淘宝网和拍拍网的竞争下，迅速丧失市场领先地位，市场份额逐步缩小，并终于与TOM集团有限公司下属的TOM在线成立了合营公司。 本文主要运用翁君奕教授的《商业模式创新》理论，以合营公司的成立为研究截止时间，尝试揭示、分析、解释EBAY易趣商务模式针对中国大陆市场而言存在的不足之处，并提出实现转机的若干建议。全文共分五章，分别如下： 第一章主要介绍论文写作的背景和研究意义所在，以及研究理论和框架。 第二章针对EBAY易趣商务模式，按照商业模式创新理论的层次，从商务模式环境、商务模式要素、...eBayEachnet and Taobao are main competitors in China’s E-commerce. eBayEachnet just took the lead in as earlier as year 2002, however, it was overwhelmed by Taobao and Paipai gradually, the leading was lost and the share market diminished very soon, as a result, it incorporated with Tom Online, a filial of Tom group limited company.Bearing in mind the theory of <Business Models Innovatio...学位：工商管理硕士院系专业：管理学院工商管理教育中心（MBA中心）_工商管理硕士(MBA)学号：20041523

End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.

Erythropoisis stimulating agent (ESA) use was addressed in Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings between 2004 and 2008. FDA safety-focused regulatory actions occurred in 2007 and 2008. In 2007, black box warnings advised of early death and venous thromboembolism (VTE) risks with ESAs in oncology. In 2010, a Risk Evaluation Strategies (REMS) was initiated, with cancer patient consent that mortality and VTE risks were noted with ESAs. We report warnings and REMS impacts on ESA utilization among Veterans Administration (VA) cancer patients with chemotherapy-induced anemia (CIA). Data were from Veterans Affairs database (2003-2012). Epoetin and darbepoetin use were primary outcomes. Segmented linear regression was used to estimate changes in ESA use levels and trends, clinical appropriateness, and adverse events (VTEs) among chemotherapy-treated cancer patients. To estimate changes in level of drug prescription rate after policy actions, model-specific indicator variables as covariates based on specific actions were included. ESA use fell by 95% and 90% from 2005, for epoetin and darbepoetin, from 22% and 11%, respectively, to 1% and 1%, respectively, among cancer patients with CIA, respectively (